Comparison of Terbinafine and Itraconazole in patients of tinea cruris
Not Applicable
- Conditions
- Health Condition 1: L00-L99- Diseases of the skin and subcutaneous tissueHealth Condition 2: L00-L99- Diseases of the skin and subcutaneous tissue
- Registration Number
- CTRI/2023/05/052604
- Lead Sponsor
- AGMC GBP Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
ALL NEWLY DIAGNOSED TINEA CRURIS SUBJECTS HAVE NOT RECEIVED ANTIFUNGAL IN LAST 14 DAYS
Exclusion Criteria
PREGNANT AND LACTATING WOMEN
PATIENTS ON IMMUNOSUPPRESSIVE DRUGS
PATIENTS UNWILLING FOR A REGULAR FOLLOW UP
PATIENTS WITH RELAPSE AND RECURRENT CASES OF TINEA CRURIS
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Erythema, Scaling, peripheral spread to other body sitesTimepoint: After 14 days and 42 days of treatment
- Secondary Outcome Measures
Name Time Method FTTimepoint: 42 DAYS